like secular winner on-line recruit russia ci
investor intrigu take wait approach
ad littl growth algorithm
expand neuromuscular franchis
wrap kra inhibitor
day focusccoi sdn on-ramp
ada stop medic meet calendar
frame mexico tariff impact
red mud outag profit red aa smelter alumina suppli
work bench depth testament psr
thesi chang what worth
trailblaz start
result point deterior outlook
close marge-in posit sophia data
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result
investor awar firm may conflict interest could affect object report investor consid report
singl factor make invest decis
like secular winner on-line recruit
russia ci
initi coverag headhunt group outperform rate target price
primari beneficiari secular shift on-line recruit on-line account total
recruit spend russia ci gap headhunt competitor
wide clear cut second place oper abil scan curriculum vita cv
databas right candid offer better solut vs classifi believ hhr
continu captur disproportion share budget shift offlin on-line
multipl driver on-going revenu growth arpc inflat smb adopt tier
price headhunt usual increas price annual current address
larger account revenu address smb
client headhunt current price model discrimin region/dur servic
see potenti implement tier price captur addit budget share particularli
client larger hr depart
option address hr manag softwar stack potenti foreign hcm
oper unlik devot much resourc ci option remain headhunt
becom one-stop solut end headhunt own oper talantix
also recent acquir stake skillaz address larger enterpris
valuat line valuat methodolog internet coverag univers tp
base dcf assum wacc termin growth rate risk includ
competit macroeconom downturn geopolit event lack price inflat
frame mexico tariff impact
price month
mexico matter propos -mexico tariff expect implement june
increas octob signific impact north american
light industri compromis still base case think prudent tri frame
potenti impact tariff move forward importantli sever tier light oem use mexico
manufactur base thu creat collect industri impact think result price
china light aspir key frame discuss potenti industri impact
mexican tariff would disadvantag acuiti mani industri
supplier thu far chines fixtur target renov market custom
price sensit typic complet project without light agent chines oem
succeed market focus high volum form factor commerci troffer
produc low cost sold direct e-commerc channel
significantli differ busi model versu new construct focus specifi product
util light design agent channel think chines oem want
challeng new construct market today prior announc /mexico tariff
expect see oem gain back market share new product introduct
contractor select acuiti market new tariff would make product
less competit chines import
valuat decreas tp base
adjust ep estim tp equat ebitda
continu see ebitda growth come quarter think stock abl
least sustain lower half two-year trade band risk includ asian competit
decreas price realiz slowdown construct market
red mud outag profit red aa
recent outag alumina refineri china unlik materi impact
alumina market beyond next month view red mud leak caus two
refineri china suspend product jiaokou huaq estim per month
loss next month note inventori digest system new refineri
china ramp mitig part suppli issu mysteel also
note alumina shanxi glut red mud outag spot price april hit lowest
atlant basin surplu alumina recent ralli chines alumina support
price given wider arbitrag pariti australia remain cautiou
medium term especi atlant basin new suppli includ alunort capac
month start-up ega al taweelah today set ramp
restart alpart rise
updat model view ebitda street lower
estim reflect lower mark market modestli lower lme price ahead
lower ebitda forecast lme alumina
lower tp capital-expenditure risk rise revis tp assum primari segment trade
ev/ebitda estim assum ebtda margin see aa upstream
smelt asset low valu given cost structur roa cycl near
australian press note appli epa permit expand pinjarra
maximum allow level per environment approv brownfield alumina expans
cost vs greenfield epa applic note construct period
risk lme price higher growth capital-expenditure
price month
revisit correct declin versu xli
oil sinc market peak surpris see
impact oil price think recent sell-off underappreci emerson exposur
upcom invest intern margin lever gener remain top pick
along ir stock high oil correl includ gdi
cloud cycl still track see tariff commod price volatil near-term
cloud detractor long-term view industri still forecast add
capac order meet supply/demand imbal anticip project order
growth
alreadi pull intern lever march quarter segment impact
moder demand upstream aftermarket global discret market climat
recoveri extend due slower se asia middl east interlink
announc acceler restructur reduc investment/ discretionari spend
result ramp howev adjust benefit time increment
margin ex-acquisit
structur gener stori expect gener excess net
incom next sever year pull work capit acquisit tool
maintain framework estim balanc sheet earn power
ep deploy share repurchas period
valuation/risk target price previous repres
ep equat yield line
group also sum-of-the-part valuat risk includ pace
develop oil price volatil demand hvac product capit deploy decis
price month
work bench depth
testament psr
posit investor day macro backdrop becom uncertain day
walk away investor day toronto includ site visit yard/
brampton intermod termin showcas proprietari technolog increas
confid compani long term trajectori remain right
question bench depth breadth one import takeaway
view wit first-hand strength depth bench say
dozen mid-level managers/employe met collect understood cultur
underpin work would understat hallmark
cultur crucial often overlook soft aspect hunter legaci lest forget there
reason former cn exec shown senior role nearli everi class last
clear sight mid-to-high teen think recent neg investor sentiment
misplac least longer term view given rel defens stock well
improv return profil cn remain sole class consist outgrow peer psr
longer term impli higher sustain growth rate consid
substanti pipelin growth matter expect
sound conserv normal capital-expenditure clear line sight
target
trim est rais tp spite posit lt view trim estim
account volum track lower initi forecast lower ep estim
forecast fall
respect tp roll forward base year dcf
model main risk macro slowdown maintain outperform
price month
gamestop report weak result incl pre-own gross profit dollar
reinforc concern stori abil stabil oper profit new
manag laid initi plan improv result paper make sens
timelin potenti reinvest requir remain unknown time compani
also battl extern factor incl wane cycl increas digit penetr continu
weak pre-own
lower estim slightli lower interest expens off-set
assumpt share repurchas well revis pre-own margin
expect price action improv valu proposit ep goe
lower tp equat
ep consist prior cycl risk downsid includ declin pre-
own higher invest upsid greater expect cost save benefit
upcom sale initi
still target profit improv progress initi focu
area incl reduc cost address oper ineffici improv store experi
improv price markdown manag test new revenu stream continu
believ sever meaning opportun improv within compani
control howev get excit transform need see evid
compani inde found altern revenu stream mitig impact growth
dividend elimin realloc capit dividend elimin entir surpris
move pay debt prudent said implic dollar may
realloc transform initi add risk time gross profit alreadi declin
shake key one cash flow opportun highlight
reduc inventori compani look declutt store focu product
price month
thesi chang what worth
remain outperform rate follow disappoint result sent pvtl stock
nearli after-hour trade result guidanc lead us believ shift container
architectur kubernet disrupt pvtl origin expect
time stock trade ev/recur revenu ntm pivot valu
orient thesi believ equiti price line intrins valu instal
base busi see potenti self-help even strateg option part
broader famili
disappoint among sever disappoint metric rpo y/i vs mid-teen
guidanc guid flat despit good larg mega win
airforc deal disclos last week anecdot acceler expans pk
sale increasingli led manag cite combin sale execut evolv
complex technolog landscap come away question deeper impact
kubernet busi true address market size strateg believ
pivot pa kubernet well situat play container architectur
earli day product enterpris workload shift best slow custom
decis possibl wors may prove somewhat deflationari
what worth base floor valu analysi sensit thereof believ
repres floor valu stock assum exist recur revenu harvest akin
financi buyer pe firm might view compani see increment strateg valu
beyond
chang estim revis revenu y/i
driven greater declin servic revenu vs prior fewer net new custom
logo downward revis subscript revenu estim vs prior
competit failur add logo expand exist custom
price month
trailblaz start
reiter outperform rate target price follow solid surpass
jitteri investor expect out-performance broad base notabl strength mulesoft
help drive y/i constant currenc current rpo growth organ constant currenc
bill growth revenu guidanc maintain vs typic rais crpo
slightli expect manag cite increment fx headwind continu
sustain demand cloud-en acuity/agil busi increas focu serv
end-customerand believ tailwind endur market cycl
like calcul bill y/i y/i organ cc surpass
expect y/i growth sale cloud growth slightli reacceler
remain y/i growth non-gaap gm highest past quarter driven
scale return previou invest ocf better consensu
expect non-gaap ep excl strateg invest gain vs street
like less current rpo slightli street
guidanc though impact fx current organ book
line expect current rpo guid y/i
growth street expect y/i growth guidanc reiter
out-performance sole driven mule out-performance organ cc y/i growth line
expect oper expens slightli street model
chang model increas revenu ep estim
risk includ execut challeng integr acquisit
slowdown spend
price month
result point deterior outlook
canadian bank report rel underwhelm result sever miss
expect come quarter grown increasingli concern
deceler growth canadian bank even weaker
below-consensu expect sign credit loss normal
believ still earli stage becom increasingli promin headwind
next coupl year
modestli reduc ep estim group reflect slightli weaker margin
canada modestli higher loan loss ratio target price declin averag
valu group use averag multipl ep
prior earn rate chang continu strongli favor td
top pick bn non-domest exposur
key trend saw includ
sign normal loan loss aggreg loan loss ratio
bp expect last quarter bp last year expect
gradual uptick toward bp rang end
canadian much weaker expect averag adjust earn growth
segment slightli roughli half level imbed consensu
estim convict growth slow less
particularli given grow potenti margin contract
exposur becom import segment gener strong bank
averag earn growth continu prefer non-domest exposur
expect outperform canadian lend busi materi
capit market rebound outlook modest rebound quarter follow
challeng howev underli result weak oper leverag neg
eighth consecut quarter see modest growth outlook busi tailwind
loan loss recoveri wear
valuat provid modest upsid bank trade market-
cap weight forward pe multipl ntm consensu remain comfort
histor averag view discount larg reflect broader market sentiment
sour past sever month weaker econom outlook trade-rel risk
see meaning upsid group absenc broader recoveri equiti
growth outlook beyond outlin investor day expect adj
ep least vs cons/cs expect mid-singl digit
percent adj ep growth compar cons/cs
beyond expect grow adjust ep low-doubl digit percentag growth rang
revenu earn growth segment hc benefit aetna expect
revenue growth mid-singl digit oper incom growth high singl digit retail/
expect low mid-singl digit revenue growth low singl digit op incom growth
pharmaci servic segment expect revenu declin low mid-singl digit
rang op incom declin mid-singl digit rang
synergi target increas initi expect drive signific save
updat year-two aet synergi target origin mln goal mln synergi
grow million run-rat beyond addit develop
enterpris modern initi seek improv product across enterpris
expect remov bln net cost final see signific valu
come transform initi project drive mln increment
oper incom grow bln lt expect three initi
drive bln increment oper profit
put take pbm busi current experienc transient headwind
 compani expect diminish respect sell
season ytd billion gross new busi howev due cnc decis
carve-in pbm non-renew net new busi expect
approxim billion project revenu howev believ return
price month
host presid mark dougla cfo andrew sandif london
chemic ag confer key takeaway
stori still teeth remain top lt pick investor interest remain high
sentiment cautiou cse optimist post key topic discuss magnitud
na weather headwind ii convict lt growth opportun especi vs global cpc iii
cost headwind ai procur iv global competit cpc environ abil
improv cash flow convers perspect remain well posit continu
outgrow cpc market materi rais margin improv cash convers unpreced
na weather concern due prevent plant acreag control
unpreced advers na weather drive uncertainti current us
acr behind corn plant acr soy plant vs prospect plant
report precipit expect week first stress us farmer capabl
get crop ground expediti pace due inclement weather project
next day along past key prevent plant date believ risk
us cpc volum applic risk well known manag although lack
weather improv earli june increas probabl greater industri headwind
perspect abil cpc produc get catch-up applic juli onward post
emerg etc minim overhang key minim investor
fear specif recal total na revenu total incl canada
larg prorat still deriv cotton citru wont ignor risk
believ global balanc intra-u crop distribut exposur valuabl off-set
enabl platform materi outperform peer
close marge-in posit
increas granular new data today macrogen present full
data octob interim analysi sophia trial margetuximab marg vs
herceptin patient metastat breast cancer overal data ident
number abstract addit surviv curv progression-fre
surviv overal surviv os visual data help attempt predict
ultim matur data may look like os data particular immatur draw safe
conclus either direct point next interim analysi expect like
next sever month
question remain head interim readout notic investigator-
base analysi includ higher number patient larger benefit
central lab-bas analysi dispar measur normal look
see increas patient event benefit central-bas analysi well compani
also mention imbal margetuximab arm patient homozyg
 allel patient difficult treat cancer older
heavili pretreat v/v patient marg arm consid patient poorer
outcom possibl group disproportion affect surviv result
outcom could reveal next analysi
price month
refin product sale would like fund mesquit purchas ngl
expect issu addit common equiti mean remain requir fund
would like includ combin debt asset sale prefer equiti view sale
refin product busi current review like way fund
mesquit given potenti de-lever benefitsa signific portion ngl work capit
borrow relat refin product valu refin product impli
multipl low end guidanc ngl current overal trade level
ebitda fund remaind acquisit current model addit
prefer equiti remain fund debt
updat estim guidanc assum refin product sale ngl provid first
time ebitda guidanc expect account roughli half
ebitda guidanc impli yoy growth includ
mesquit acquisit management highlight higher wastewat fee due increas exposur
new mexico well lower opex/bbl higher proport pipe volum key driver
growth increas ebitda estim increas crude
water ebitda partial off-set assum sale refin product segment
estim sale refin product segment would allow mesquit transact remain
leverag neutral total leverag vs
maintain neutral rate tp maintain neutral rate tp base
ebitda current trade level
risk upsid risk includ higher anticip valuat potenti refin product
sale downsid risk includ sale refin product segment addit equiti
issuanc fund mesquit acquisit
investor intrigu take wait
approach
bottom line numer convers investor last week
sinc publish detail look combin bristol/celgen host investor lunch
discuss bull bear thesi stock chat variou investor
provid detail feedback investor convers gener theme
like valu name also rush get
stock ahead upcom data readout close celgen acquisit
focu expect note last week focus asset
celgen bring combin compani oppos bristol alreadi
howev surpris much focus investor seem right
upcom lung cancer data part opdivo yervoy part
data point clear first consist heard expert spoke
expect posit data seem quit low although seri underwhelm
dataset opdivo opdivo yervoy lung cancer seem keep investor
sidelin data pass convers suggest downsid possibl
disappoint data potenti upsid data suggest bristol get
meaning share line non-smal cell lung cancer market
could investor look get bristol wait
price month
ad littl
analyst day recap versac choo though versace/ choo
ebit year target impli drive increment ebit growth
next yr didnt get much detail behind what drive cadenc multi-yr margin
improv versace/choo combin ebit margin impli inflect yoy
vs said convers today suggest versace/choo
manag optimist attach cpri big market budget support
advertis behind big ideasbolst convict brand achiev fairli
aggress target take step back global brand lsd/msd ebit
margin today vs peer mid/high-teen big margin driver push high-
kor brand remain concern long-term target still much reli stabilizing/
improv kor brand trend impress big push rapidli grow
categories/geographi sneaker men asia didnt hear anyth today help us see
long-term path toward share gain categori growth brand core us women
accessori biz heard concern detail around brand margin
drag next year lower wholesale/licens mix watch consist
neg callout licens wonder kor plan left enough flexibl brand
show sign could need anoth big step back non-watch wholesal categori
valuat kor still ebit today need evid kor comp
stabil take construct stanceeven valuat becom signific
outlier tp base ebitda
expand neuromuscular franchis
ind clear immune-medi necrot myopathi imnm rarx track
commenc zilucoplan phase clinic trial treatment imnm pbo-
control trial enrol subject random stratifi base antibodi statu
primari efficaci endpoint chang creatin kinas ck level baselin week
imnm diseas activ gener associ elev ck level given promin
manag emphas zilucoplan potenti differenti mab inhibitor
may dose top ivig patient allow enrol stabl background
therapi includ chronic ivig offer protect indic minim potenti
imnm potenti venu valu creation see trial design adequ provid
proof-of-concept believ indic worth explor consid deposit
commonli found diseas zilucoplan establish efficaci complement-driven gmg
somewhat mixed/limit efficaci current soc gener immunosuppress
believ indic offer potenti upsid stock rarx estim anti-srp /anti-
hmgcr patient us/eu/jp approv therapi literatur suggest
patient progress incomplet recoveri year despit intens
immunosuppress believ investor like await clinic data prior assign
substanti valu program though could see valu build stock ahead
expect top-lin data
price month
wrap kra
quieter acso data solid tumor clear focu coverag
univers dust settl sinc hope attend made
home safe recap highlight key takeaway coverag overal
would character year meet rel quieter compar previou year
still sever key relev present much data earli think data
set matur clariti regulatori path becom appar could see share upsid
name less gilead
global biopharma wrap call friday et summar data
meet also co-host asco wrap-up confer call physician
expert discuss key data releas confer data impact clinic practic
go forward pleas join us friday june et dial us
positivesupport outperform thesi tp present
meaning among coverag univers saw better-than-expect data
highli anticip inhibitor solid tumor show respons
rate nsclc target previous consid undrugg decad attempt
elicit clinic respons data present may first success seen tumor
mutat howev question remain regard registr path efficaci
also saw updat bite proprietari bispecif asset data anti-bcma
mm initi clinic data anti-psma mcrpc data hematolog
malign could see bi-specif challeng car-t therapi howev current avail
data still immatur safeti concern remain abl manag toxic produc
deep durabl respons subsequ trial bite platform could competit threat
car-t treatment greater usabl due faster time administr potenti lower
along line gener sentiment toward car-t confer highlight
signific payer headwind practic hurdl drug administr think
commerci sale yescarta highlight challeng could present opportun bispecif
compet specif regard thought updat data still encourag
less excit compar concern infect risk highli competit
bcma space thought data interest given combin
efficaci better safeti profil drug also first bite use solid tumor
unmet need extrem high howev cautious optimist data earli much
remain seen use bite target solid tumor
think half-lif extend hle bite potenti easier commerci
given practic hurdl continu infus similar car-t howev still
reserv extend half-lif bite consid toxic saw
bite continu infus provid advantag mitig turn
pump immedi stop drug remov option could see worsen
still consider work ahead address issu look forward hear
updat hle version later year still challeng think
oncolog platform becom import investor greater clariti
approv pathway could drive signific share upsid could
import increment driver safeti profil dose improv
solid tumor interim phase data like efficaci
patient nsclc respond treatment good safeti profil dlt
acknowledg trial small challeng extrapol data larger popul
charl martineau pm univers toronto howev physician expert believ data could support eventu regulatori
approv particularli continu durabl concern may limit
patient achiev stabl diseas sd vs pr cr amgen investor
event monday night inform given regard path regulatori approv despit
high investor interest overal high-valu target could see signific share
upsid compani provid clariti potenti regulatori approv
anti-bcma mm efficaci present last seen
gener unchang show orr mrg-neg like efficaci
concern safeti profil peripher neuropathi patient
grade infect risk note dlt trial larg
confin higher dose bcma remain import target potenti market
multipl myeloma could see compet car-t improv safeti
profil dose
pasotuxizumab anti-psma mcrpc first bite foray solid tumor show
encourag data drug demonstr appropri dose-depend respons two long-
term respond month one long-term respond mcg/d dose
show reduct psaan import marker correl diseas progress
safeti profil patient experi grade lymphopenia infect
common despit high incid profil potenti toler
consid limit option highli advanc diseas popul similar
concern safeti dose dose-escal studi would help increas convict
along hle formul overal efficaci interest data earli
larger trial need confirm util prostat cancer
gilead neutralsupport neutral thesi tp
gener sentiment car-t somewhat neg despit encourag efficaci
clinician highlight difficulti face car-t use real world cite increas
challeng payer approv manufactur setback pushback administr
see headwind translat lower-than-expect sale car-t includ gilead
yescarta commerci disappoint challeng face car-t support
gener view car-t excel patient challeng remain efficaci
overal eas use overal believ data gilead car-t franchis significantli
stock move given commerci challeng face yescarta franchis
autolog car-t r/r data present phase trial show
compel efficaci data cr/cri rate show undetect mrd
big challeng scientif perspect safeti profil better mitig sinc
last updat new ae manag guidelin howev still seriou
concern safeti consid patient endur grade drug could still help
expand util gilead car-t franchis expect modest upsid given broader
commerci challeng competit space
regeneron negative/neutralsupport neutral thesi tp
advanc cancer combin data libtayo
underwhelm monotherapi show clinic respons
combin drug data present show appropri dose-respons efficaci
modest patient show pr furthermor safeti profil mix
teae either monotherapi combin arm data still earli longer durat
treatment could potenti see clinic effect stock perspect data
support view regeneron earli emerg pipelin could drive share
upsid futur howev data present earli us includ meaning credit
valuat
neutral/positivesupport neutral thesi
capmatinib anti-met nsclc highli posit registration-en
data present entitl royalti capmatinib out-
licens novarti significantli limit upsid despit high efficaci clean
safeti profil efficaci data present show high durat respons dor treatment-
experienc month treatment-nav month patient progress free surviv
also compel month treatment-experienc treatment-nav
patient respect safeti profil well toler peripher edema
common ae capmatinib expect gain regulatori approv see
capmatinib stock move consid limit econom smaller market
mutat patient nsclc
pleas find link addit note publish confer
charl martineau pm univers toronto host two key opinion leader monday morn get insight data
present weekend
publish summari report sunday highlight import takeaway credit suiss
coverag univers global biotechnolog pharmaceut
day focusccoi sdn on-ramp
day highlight first day confer highlight remain confid ccoi
outperform tp busi cost advantag sustain long term free cash flow
continu grow forese futur support compani capit return mandat
neutral tp posit well new alinda jv
netherland data center solid opportun signific valu creation
softwar defin network provid posit continu growth seen
compel discuss megaport packetfabr data center oper consum
servic data center discuss confer
firesid chat ceo dave schaeffer discuss success challeng internet
servic provid isp industri low price advantag enabl achiev
revenu growth despit continu fall price broadband schaeffer also expand
signific oper leverag compani on-net busi continu grow key
strength compani recent initi outperform rate note
high dividend growth challeng market
firesid chat cfo jeff berson discuss recent develop notabl
opportunist acquisit two data center netherland distress asset
saw much potenti valu creation focu find low cost low risk
opportun acquisit common theme alinda joint ventur also
discuss key driver lift return invest capit area focu investor
investor dinner vice-president global ecosystem john knuff met investor discuss
strength marketplac role mr knuff help compani leverag
comprehens digit commerc strategi find partner meet come challeng
ensur effici depend oper dens select mobil cloud servic
provid found dinner discuss inform remain confid eqix
abil maintain strengthen interconnect ecosystem cloud arena
build one robust financi servic ecosystem world see
invest year start payoff
offer inap ceo presid peter aquino address shift provid wholesal
retail-onli tierpoint cro anthoni rossabi discuss attribut tier data center
market presid ceo richard calder cfo mike sicoli discuss organ growth
cost synergi realiz evoqu presid ceo tim caulfield discuss carrier
neutral busi chang
fed releas dfast result june ccar result june point
fast approach revisit ccar instruct scenario updat
dfast model order valid capit return expect consid
conserv interpret year scenario current etho fed
expect higher loss stress period suffici capac support
increas dollar amount net capit return cs larg cap bank
translat pay-out ccar
ccar sever advers scenario featur sever recess
compar last year scenario reflect feder reserv scenario design
framework call pronounc econom downturn current condit
especi strong compar last year scenario note normal path stress
observ extrem scenario gradual declin equiti
price credit spread widen declin long-term treasuri rate suggest potenti
attenu cost stress
earn power start take edg cost stress cs
larg cap bank come ccar process base rate earn power ppnr
estim last year level ii margin less regulatori capit averag
level still excess requir minimum support capac capit return
cost stress interpret ccar instruct translat
margin larger hit base case ppnr consist macro factor sever advers
scenario magnitud peak trough declin etc march ccar
transpar document ccar particip bank estim stress baselin
ppnr compar stress baselin ppnr ccar ii increas
stress provis expens iii reduct market-rel loss iv less
advers impact oci translat higher dollar amount stress
loss consid context capit level base rate earn power
stress level appear manag analysi indic cushion
minimum point factor capit return assumpt
host day annual credit suiss confer new york today
present corp interpubl group entertain wpp group outfront
media viacom lionsgat new york time plc advertis panel
takeaway follow
digit discuss broadli center digit strategi mani media
compani get point enough scale oper experi data analyt
monet begin gaug guid multi-year outcom
up-front up-front come stronger ad buyer expect volum flat-to-
slightli price line last year better seller argu see even
better price up-front strong initi push level quickli steadi
pace sinc tv rate declin sever season advertis burn
scatter price push up-front digit video still get enough scale
impress effect measur brand safeti issu increasingli view
intract higher-pr categori like internet direct-to-consum movi increas
demand push lower price cpg tradit publish ad revenu aid
growth digit tv platform hulu pluto etc wpp note tv still nearli much
reach peak lose mostli frequenc tune advertis still accomplish
campaign reach frequenc goal tv sport demand seem strong brand
advertis expect chase expect elect bump news channel though
bundl comcast disney lesser extent seen well posit up-front
due sell portfolio broadcast cabl digit properti note merg cbs/
viacom would move well posit bucket prime-time broadcast price rise double-
digit publish advertis benefit abil mix match lower-pr
digit advertis connect tv remain hot topic agenc increasingli think svod
connect tv inventori compon tv budget rather digit though still
vari xandr exampl present separ up-front turner continu get
mix feedback advertis notabl percept amazon significantli
reach video advertis product soon bring inventori categori
record present well day webcast may view pleas see
acceler sector trend compani detail schedul confer
ada stop medic meet calendar
bottom line follow world largest oncolog meet back road
later week world largest diabet meet american diabet associ ada
annual meet san francisco ca jun meet highlight full data
major cardiovascular cv outcom trial lead diabet drug alreadi
market lilli trulic tradjenta js invokana along detail data two novel
pipelin drug novo oral semaglutid lilli tirzepatid hope disrupt diabet
market come year
investor focus full
result rewind cv outcom trial lilli trulic may outlier view
believ detail less commerci impact concern trulic
would major disadvantag novo ozempic/victoza trulic show cv benefit
rewind howev given alreadi know think detail around variou
subgroup perform endpoint drove benefit less import class
strong volum growth driven primari care physician whose prescrib decis
often less determin detail data factor formulari posit
inject devic outcom trial analyz lilly/boehring ingelheim
carolina trial inhibitor tradjenta vs sulfonylurea amaryl js credenc trial
inhibitor invokana vs placebo patient diabet chronic kidney diseas
bar major surpris full data assum class continu lose share
credenc data provid boost whole
class expand use drug patient chronic kidney diseas howev
main beneficiari like jardianc given black warn remain invokana
label relat lower limb amput risk unless success black
remov invokana label follow new data
novo lilli hope new innov expand market domin pipelin
eager see detail data multipl trial novo oral semaglutid two-
hour session focus data asset close meet gain
insight attende nuanc around take product wait
eat may impact uptak adher lilli pipelin focu tirzepatid
phase dose escal data nash biomark data expect weekend
credit suiss upgrad novo april see novo upgrad outperform increas
oral semaglutid forecast peak overal glp sale
post victoza patent loss compar evalu consensu lilli maintain
neutral rate current estim combin trulic tirzepatid sale
vs evalu consensu combin sale estim jardianc estim end-
user sale vs evalu consensu invokana
estim vs evalu consensu
lilli novo also host investor calls/ev novo analyst meet june
pt expect discuss focu oral sema data howev also
expect discuss high-dos oral sema on-going step trial obes includ
subgroup obes diabet run may clinicaltri gov list second
studi non-obes diabet expect shortli run around time topic
may includ could see weekli insulin due
could expect novo tri-agonist lai sema weekli insulin semaglutid
combo also show result lilli host investor call
june pt expect focu detail rewind data
addit insight tirzepatid
doctor dinner monday even place data context host expert
dinner monday june pt lead endocrinologist leader
diabet devic inform manag let us know would like seat dinner
heavi truck order disappoint may class order came unit
expect low-teen rang order repres y/i declin
drop sequenti declin part driven softer freight market rate condit
addit far remain healthi class backlog furthermor fear lack
resolut around trade war begin impact demand first five month
year class order total unit significantli unit period
last year addit act project class backlog fall unit final data
releas middl month look ahead order expect averag
next month risk downsid next major data point fall time
period gain better understand order big fleet implic
product despit weaken order trend evid oe moder
medium duti order expect may class order came unit
class class order repres y/i declin
drop sequenti first five month year class order total
compar unit period last year addit act project class
backlog fall unit final data releas middl month
charl martineau pm univers toronto compani mention price
